Quotient Sciences Acquires Pharmaterials, Launches as New Global Identity for Quotient Clinical

Quotient Sciences, the drug development services organization, recently announced it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the UK, and further supports the growth of Quotient’s Translational Pharmaceutics^® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.

Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000-square feet facility that houses 13 GMP manufacturing suites, with space for future expansion.

“The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing,” said Mark Egerton, CEO, Quotient Sciences. “The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

Quotient Clinical also announced its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma, and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.

Quotient’s Translational Pharmaceutics^® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs.

“We are excited about the future of Quotient Sciences,” added Mark Egerton. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”

With over 700 employees, six operating sites across the US and UK and a 30-year track record for quality services, Quotient is focused on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.

Quotient Sciences, a global pharmaceutical development, clinical pharmacology, and clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics^® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost. For more information, visit quotientsciences.com.

Pharmaterials Ltd. is a contract development and manufacturing organization, specializing in the drug substance screening, formulation development and manufacturing of preclinical & early phase oral and inhaled dosage forms. For more information, visit pharmaterials.co.uk .